RU2014140177A - Фармацевтические антиретровирусные композиции - Google Patents
Фармацевтические антиретровирусные композиции Download PDFInfo
- Publication number
- RU2014140177A RU2014140177A RU2014140177A RU2014140177A RU2014140177A RU 2014140177 A RU2014140177 A RU 2014140177A RU 2014140177 A RU2014140177 A RU 2014140177A RU 2014140177 A RU2014140177 A RU 2014140177A RU 2014140177 A RU2014140177 A RU 2014140177A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- nevirapine
- pharmaceutical
- pharmaceutical antiretroviral
- festinavir
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 48
- 230000000798 anti-retroviral effect Effects 0.000 title claims abstract 34
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims abstract 50
- 229960000689 nevirapine Drugs 0.000 claims abstract 25
- 239000002552 dosage form Substances 0.000 claims abstract 16
- OSYWBJSVKUFFSU-SKDRFNHKSA-N festinavir Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@](CO)(C#C)O1 OSYWBJSVKUFFSU-SKDRFNHKSA-N 0.000 claims abstract 16
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims abstract 16
- 229960001627 lamivudine Drugs 0.000 claims abstract 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 10
- 238000013268 sustained release Methods 0.000 claims abstract 10
- 239000012730 sustained-release form Substances 0.000 claims abstract 10
- 229920000642 polymer Polymers 0.000 claims abstract 6
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract 4
- 229920001600 hydrophobic polymer Polymers 0.000 claims abstract 4
- 150000002148 esters Chemical class 0.000 claims abstract 2
- 230000002209 hydrophobic effect Effects 0.000 claims abstract 2
- 239000000651 prodrug Substances 0.000 claims abstract 2
- 229940002612 prodrug Drugs 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 239000010410 layer Substances 0.000 claims 15
- 239000011324 bead Substances 0.000 claims 10
- 239000003826 tablet Substances 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000007919 dispersible tablet Substances 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 4
- 239000011859 microparticle Substances 0.000 claims 4
- 239000004005 microsphere Substances 0.000 claims 4
- 239000008185 minitablet Substances 0.000 claims 4
- 239000006187 pill Substances 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 230000006806 disease prevention Effects 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 241001430294 unidentified retrovirus Species 0.000 claims 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000007903 gelatin capsule Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000011806 microball Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000541 pulsatile effect Effects 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 239000002356 single layer Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN583MU2012 | 2012-03-05 | ||
| IN583/MUM/2012 | 2012-03-05 | ||
| PCT/GB2013/000092 WO2013132208A1 (en) | 2012-03-05 | 2013-03-05 | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014140177A true RU2014140177A (ru) | 2016-04-27 |
Family
ID=47884388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014140177A RU2014140177A (ru) | 2012-03-05 | 2013-03-05 | Фармацевтические антиретровирусные композиции |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150104511A1 (enExample) |
| EP (1) | EP2822560A1 (enExample) |
| JP (1) | JP2015509524A (enExample) |
| KR (1) | KR20140138837A (enExample) |
| CN (1) | CN104203244A (enExample) |
| AU (1) | AU2013229274A1 (enExample) |
| BR (1) | BR112014021927A2 (enExample) |
| CA (1) | CA2866133A1 (enExample) |
| IN (1) | IN2014MN01907A (enExample) |
| MX (1) | MX2014010337A (enExample) |
| RU (1) | RU2014140177A (enExample) |
| WO (1) | WO2013132208A1 (enExample) |
| ZA (1) | ZA201406495B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016507569A (ja) * | 2013-02-07 | 2016-03-10 | トビラ セラピューティクス， インコーポレイテッド | ラミブジン結晶塩 |
| EP3153157A1 (en) | 2015-10-09 | 2017-04-12 | Teva Pharmaceutical Works Private Limited Company | Pharmaceutical composition for prolonged release of nevirapine |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
| PL3752495T3 (pl) | 2018-02-15 | 2024-01-15 | Gilead Sciences, Inc. | Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv |
| KR20230141905A (ko) * | 2018-07-16 | 2023-10-10 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
| JP7503558B2 (ja) | 2019-01-25 | 2024-06-20 | ブラウン ユニバーシティ | 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法 |
| AU2021296607B2 (en) | 2020-06-25 | 2024-07-25 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| HRP20250928T1 (hr) | 2021-12-03 | 2025-09-26 | Gilead Sciences, Inc. | TERAPIJSKI SPOJEVI ZA INFEKCIJU VIRUSOM HIV-a |
| EP4440700A1 (en) | 2021-12-03 | 2024-10-09 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE131730T1 (de) | 1991-05-16 | 1996-01-15 | Glaxo Group Ltd | Nukleosidanalogen enthaltende antiviren- zubereitungen |
| GB9622681D0 (en) | 1996-10-31 | 1997-01-08 | Glaxo Group Ltd | Pharmaceutical compositions |
| PT1035834E (pt) * | 1997-12-05 | 2002-09-30 | Alza Corp | Forma de dosagem osmotica que compreende primeiro e segundo revestimentos |
| PL191832B1 (pl) | 1998-01-16 | 2006-07-31 | Medivir Ab | Podstawiona pochodna N-(cyklopropylo)-N'-(pirydylo)mocznika, jej zastosowanie i kompozycja farmaceutyczna |
| GB9809213D0 (en) | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| WO2004087169A1 (en) | 2003-03-27 | 2004-10-14 | Boehringer Ingelheim International Gmbh | Antiviral combination of nevirapine and a further antiretroviral compound |
| AU2006286314A1 (en) * | 2005-08-31 | 2007-03-08 | Cipla Limited | Pharmaceutical combinations containing lamivudine, stavudine and nevirapine |
| JP5417662B2 (ja) * | 2007-06-08 | 2014-02-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネビラピンの徐放性製剤 |
-
2013
- 2013-03-05 CA CA2866133A patent/CA2866133A1/en not_active Abandoned
- 2013-03-05 EP EP13709491.8A patent/EP2822560A1/en not_active Withdrawn
- 2013-03-05 BR BR112014021927A patent/BR112014021927A2/pt not_active IP Right Cessation
- 2013-03-05 MX MX2014010337A patent/MX2014010337A/es unknown
- 2013-03-05 WO PCT/GB2013/000092 patent/WO2013132208A1/en not_active Ceased
- 2013-03-05 AU AU2013229274A patent/AU2013229274A1/en not_active Abandoned
- 2013-03-05 CN CN201380012366.4A patent/CN104203244A/zh active Pending
- 2013-03-05 KR KR20147027819A patent/KR20140138837A/ko not_active Withdrawn
- 2013-03-05 JP JP2014560438A patent/JP2015509524A/ja active Pending
- 2013-03-05 RU RU2014140177A patent/RU2014140177A/ru not_active Application Discontinuation
- 2013-03-05 US US14/382,444 patent/US20150104511A1/en not_active Abandoned
- 2013-03-05 IN IN1907MUN2014 patent/IN2014MN01907A/en unknown
-
2014
- 2014-09-04 ZA ZA2014/06495A patent/ZA201406495B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150104511A1 (en) | 2015-04-16 |
| KR20140138837A (ko) | 2014-12-04 |
| IN2014MN01907A (enExample) | 2015-07-10 |
| CA2866133A1 (en) | 2013-09-12 |
| WO2013132208A1 (en) | 2013-09-12 |
| CN104203244A (zh) | 2014-12-10 |
| AU2013229274A1 (en) | 2014-09-04 |
| MX2014010337A (es) | 2014-11-14 |
| WO2013132208A8 (en) | 2013-11-07 |
| BR112014021927A2 (pt) | 2019-09-24 |
| JP2015509524A (ja) | 2015-03-30 |
| EP2822560A1 (en) | 2015-01-14 |
| ZA201406495B (en) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014140177A (ru) | Фармацевтические антиретровирусные композиции | |
| JP7398999B2 (ja) | 薬物動態が改善された放出調節ガンマ－ヒドロキシ酪酸塩製剤 | |
| Panigrahi et al. | Gelucire: A versatile polymer for modified release drug delivery system | |
| CN103917231B (zh) | 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途 | |
| KR101413613B1 (ko) | 약 염기성 선택성 세로토닌 5-ｈｔ3 차단제와 유기산을 포함하는 약물 전달 시스템 | |
| RU2616516C2 (ru) | Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль | |
| JP2012144577A5 (enExample) | ||
| US10182993B2 (en) | Compositions for colonic delivery of drugs | |
| CN101972236A (zh) | 一种含吡非尼酮的缓释制剂 | |
| JP2009517466A5 (enExample) | ||
| JP6957610B2 (ja) | 医薬品用途のための多層ビーズ | |
| CN108348475A (zh) | 处于液体剂型的多层药学活性化合物释放微粒 | |
| US20230055404A1 (en) | Solid preparation, and preparation method therefor and use thereof | |
| CN101703513A (zh) | 阿司匹林和氯吡格雷或其药学上可接受的盐的复方缓释制剂 | |
| CN105338970A (zh) | 包含他达拉非和坦洛新的药物胶囊复合制剂 | |
| JP2019532939A5 (enExample) | ||
| ES2899885T3 (es) | Nueva composición farmacéutica de liberación diferencial que contiene tres principios activos | |
| CN102772392B (zh) | 一种阿比多尔缓控释胶囊及其制备方法 | |
| EP3496719B1 (en) | A multi-class anti-retroviral composition | |
| AU2021402764A1 (en) | Pharmaceutically stable soft capsule comprising two or more different compositions | |
| WO2017029226A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| JP5919173B2 (ja) | 徐放性塩酸アンブロキソール口腔内崩壊錠 | |
| CN103142518B (zh) | 一种阿格列汀脂质体固体制剂及其制备方法和应用 | |
| CN101766608B (zh) | 复方盐酸伪麻黄碱缓释制剂及其制备方法 | |
| KR20150105496A (ko) | 다폭세틴 및 염산클로미프라민으로부터 선택되는 조루치료제 및 pde5 억제제가 분리된 형태로 존재하는 경구투여 약제학적 제형 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170615 |